HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China TCM (570.HK) - Latest Updates on Privatization and the Potential Merger with Taiji Group

China TCM (570.HK) Update - Despite Doubts, This Privatization Seems “Mandatory”

China TCM (570.HK) Privatization Update - Investors May Need to Prepare for a Longer Wait

L'Occitane (973.HK) Privatization - The Offer Price Is Good Enough

Event-Driven

China Traditional Chinese Medicine / Event-Driven

China Traditional Chinese Medicine (570 HK)

<ul>
<li>The slow progress of privatization is related to recent high-level changes in CNPGC. Decisions on SOE deals with "strategic purpose" require careful considerations, not based on "one leader’s personal preferences".</li>
<li>Based on public information, we cannot find convincing reason to prove that CNPGC has changed its mind.There’re rumors that China TCM’s privatization is still considered important project on the agenda.</li>
<li>China TCM’s has strong fundamentals to support valuation. If there is no announcement, the privatization process is expected to proceed as usual, and we continue to wait for the voting.  </li>
</ul>


The slow progress of privatization is related to recent high-level changes in CNPGC. Decisions on SOE deals with "strategic purpose" require careful considerations, not based on "one leader’s personal preferences".
Based on public information, we cannot find convincing reason to prove that CNPGC has changed its mind.There’re rumors that China TCM’s privatization is still considered important project on the agenda.
China TCM’s has strong fundamentals to support valuation. If there is no announcement, the privatization process is expected to proceed as usual, and we continue to wait for the voting.  


China TCM (570.HK) Update - Behind The Share Price Plunge and Prospects for Privatization Progress